The Antibody Production Market size was estimated USD 16.4 billion in 2022 and is expected to reach USD 44.2 billion by 2030 at a CAGR of 13.2% during the forecast period of 2023-2030.   

The antibody production market is a rapidly growing sector within the biotechnology industry. Antibodies, also known as immunoglobulins, play a crucial role in the immune system by identifying and neutralizing foreign substances such as bacteria, viruses, and toxins. With the increasing prevalence of diseases and the need for effective therapeutics, the demand for antibodies has surged significantly.

One of the key drivers behind the growth of the antibody production market is the rising incidence of chronic diseases such as cancer, autoimmune disorders, and infectious diseases. Antibodies have shown immense potential in targeted therapy and precision medicine approaches. They can be engineered to specifically bind to certain molecules or cells involved in disease progression, enabling more effective treatment options.

Get Free PDF Sample Report: https://www.snsinsider.com/sample-request/3716

Moreover, advancements in technology have revolutionized antibody production methods. Traditional methods involved extracting antibodies from animals or human donors, which had limitations in terms of scalability and consistency. However, with the advent of recombinant DNA technology and hybridoma techniques, scientists can now produce monoclonal antibodies (mAbs These advancements have not only improved the scalability and consistency of antibody production but have also allowed for the development of novel therapeutic antibodies. By manipulating the genetic code, scientists can now create antibodies with enhanced properties such as increased potency or improved targeting capabilities. In addition to their use in disease treatment, monoclonal antibodies have also found applications in diagnostics. They can be utilized to detect specific molecules or cells in patient samples, aiding in the early detection and monitoring of diseases. Furthermore, the development of antibody-drug conjugates (ADCs) has opened up new possibilities in targeted therapy. By attaching potent drugs to monoclonal antibodies, ADCs can deliver the medication directly to diseased cells while minimizing damage to healthy tissues. Overall, the advancements in antibody production methods and the utilization of monoclonal antibodies have significantly expanded the possibilities for more effective and targeted treatments in the field of medicine.

KEY MARKET SEGMENTS

By Product

  • Instruments
    • Bioreactors
      • Multi-use Bioreactors
      • Single-use Bioreactors
    • Chromatography Systems
    • Filtration systems
  • Consumables
    • Media
    • Buffers and Reagents
    • Chromatography Resins and Columns
    • Filtration Consumables and Accessories
    • Others
  • Software

By Process

  • Upstream Processing
  • Downstream Processing

By Type

  • Monoclonal Antibody
  • Polyclonal Antibody

By End User

  • Pharmaceutical and Biotechnology Companies
  • Research Laboratories
  • CROs and CDMOs

Major Players Listed in the Report are as Follows:

Illumina, Inc., Thermo Fisher Scientific, Inc., Pacific Biosciences of California, Inc., Bio-Rad Laboratories, QIAGEN, Agilent Technologies, PerkinElmer, Inc., ProPhase Labs, Inc. (Nebula Genomics), Novartis, Psomagen, Azenta US, Inc., and Others.

About US:

SNS Insider has been a leader in data and analytics globally with its authentic consumer and market insights. The trust of our clients and business partners has always been at the center of who we are as a company. We are a business that leads the industry in innovation, and to support the success of our clients, our highly skilled engineers, consultants, and data scientists have consistently pushed the limits of the industry with innovative methodology and measuring technologies.

We assist our clients to anticipate industrial, economic, and consumer trends to drive disruptive change by fusing global experience with local information from experts throughout the world. We bring context to strategic and tactical data by bridging approaches based on data science and field research, assisting you in addressing your most pressing problems and spotting possibilities.

Contact Us:

Akash Anand – Head of Business Development & Strategy,

[email protected],

Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)